IMNM Share Price Performance
US$10.95
-1.41 (-11.37%)
Price US$10.95
Share PriceUS$10.95
IMNM Community Narratives
There are no narratives available yet.
Recent IMNM News & Updates
No updates
Immunome, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.36
- Gross Margin
- -1,280.92%
- Net Profit Margin
- -1,875.21%
- Debt/Equity Ratio
- 0%
Immunome, Inc. Competitors
About IMNM
- Founded
- 2006
- Employees
- 131
- CEO
- WebsiteView website
Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 13.1%
- 1 Year: 22.8%
- Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading